ACC Congress coverage: the interventional cardiology perspective

Jonathan Curio provides his take on TRISCEND II trial results presented by Vinod H. Thourani at ACC.26 in New Orleans.

Mirvat Al Asnag provides her take on the ALL-RISE randomised trial presented by Ajay J. Kirtane at ACC.26 in New Orleans.

During the first Late-Breaking Trial session of the 2026 ACC Congress held in New Orleans, Saibal Kar, principal investigator of the CHAMPION-AF trial, presented the 3-year results of this groundbreaking study, which were simultaneously published in the NEJM (DOI: 10.1056/NEJMoa2517213).

Ali Nazmi Calik provides his take on the results of the OPTIMAL trial presented by Luca Testa at ACC.26 in New Orleans.

Alex Sticchi interviews Erwan Donal on the 2-year outcomes of the TRI-FR randomised trial evaluating transcatheter tricuspid edge-to-edge repair (T-TEER) versus medical therapy alone, as presented at ACC.26 in New Orleans.

Aaysha Cader interviews Divaka Perera on the CHIP-BCIS3 randomised trial, which evaluated whether elective left ventricular (LV) unloading during high-risk PCI improves outcomes in patients with severe LV dysfunction, extensive coronary disease, and complex procedures, as presented at ACC.26 in New Orleans.

Nicola Ryan provides her take on the 10-year follow-up of the HOST-EXAM, which was presented by Hyo-Soo Kim at ACC.26 in New Orleans.

Nicola Ryan provides her take on DKCRUSH-VIII, a randomised controlled trial comparing IVUS versus angiography guidance for PCI, predominantly using the DKCRUSH technique in patients with complex bifurcation lesions, as presented by Shaoliang Chen at ACC.26 in New Orleans.

Daniele Giacoppo reports and provides his perspective on the main results of the IVUS-CHIP trial, presented by Roberto Diletti from the Erasmus University Medical Center, Rotterdam, the Netherlands, during a Late-Breaking Trials session at the ACC.26 in New Orleans, and simultaneously published in the New England Journal of...

Alex Sticchi interviews Adam B. Greenbaum on the PROTECT head-to-head trial, comparing the new full-body Emboliner device with the first-generation Sentinel during TAVR, as presented at ACC.26 in New Orleans.